InsiderTradr

Nectar Lifesciences Limited (NECLIFE.NS)

NSE · INR · Healthcare · Drug Manufacturers - Specialty & Generic

₹10.34 (-1.80%) as of

Key statistics

Market cap
2.01B
P/E (TTM)
29.54
Forward P/E
3.48
EPS (TTM)
0.35
Dividend yield
0.00%
52-week range
9.30 – 22.40
Beta
0.66
Revenue (TTM)
145k
Profit margin
0.00%
Volume
129.86k

About Nectar Lifesciences Limited

Nectar Lifesciences Limited manufactures, distributes, markets and sells pharmaceutical products in India and internationally. The company offers cephalosporins, includes pharmaceutical ingredients and intermediates comprising cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium, ceftriaxone sodium, cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil and sterile, cefprozil, cefdinir, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate, and cefepime +Arginine. It also provides contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins. In addition, the company offers menthol and pearl capsules. Further. It exports its poducts. Nectar Lifesciences Limited was incorporated in 1995 and is based in Chandigarh, India.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Headquarters
Chandigarh, India
Employees
111

neclife.com

Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.

Related stocks